Abdominal Radiology

, Volume 43, Issue 4, pp 861–879 | Cite as

Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group

  • Andrej Lyshchik
  • Yuko Kono
  • Christoph F. Dietrich
  • Hyun-Jung Jang
  • Tae Kyoung Kim
  • Fabio Piscaglia
  • Alexander Vezeridis
  • Juergen K. Willmann
  • Stephanie R. Wilson
Article

Abstract

Contrast-enhanced ultrasound (CEUS) is a specific form of ultrasound imaging performed with intravenous administration of microbubble contrast agents. It has been extensively used for liver tumor characterization and was recently added to the American College of Radiology Liver Imaging Reporting and Data System (CEUS LI-RADS). This paper describes technical recommendations for successful liver CEUS lesion characterization, and provides imaging protocol and Lexicon of imaging findings.

Keywords

Liver Ultrasound Contrast-enhanced ultrasound 

Notes

Acknowledgments

The authors would like to dedicate this manuscript to our dear friend Dr. David Cosgrove (1938–2017). David was a thought leader in the clinical ultrasound and a passionate advocate of CEUS. He was one of the founding members of the CEUS LI-RADS Working Group and spent countless hours working on this project. His extraordinary knowledge, enthusiasm, and dedication were extremely valuable and will be greatly missed. Supported in part by NCI Grant R01 CA215520-01A1.

Compliance with ethical standards

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

Andrej Lyshchik: Research support: GE, Siemens, Toshiba; Advisory Board: Bracco; Speaker: GE, SonoScape. Yuko Kono: Research support: Toshiba, GE, Lantheus. Christoph F Dietrich: Advisory Board; Hitachi, Mindray, JAZZ. Speaker: Hitachi, Supersonic, Siemens, Mindray, GE, Bracco, Pentax, Novartis. Hyun-Jung Jang: none. Tae Kyoung Kim: none. Fabio Piscaglia: Research support: Esaote; Advisory Board: Bayer, Eisai; Speaker: Bracco, Bayer. Alexander Vezeridis: none. Juergen K Willmann: Research support: Siemens, GE, Philips, Bracco; Consulting: Bracco, Triple Ring Technologies; Advisory Board: Lantheus, Bracco, SonoVol. Stephanie R Wilson: Research support: Siemens, Philips and Samsung; Speaker: GE and Samsung

References

  1. 1.
    World Health Organization (2012) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2017. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
  2. 2.
    Mitchell DG, Bruix J, Sherman M, Sirlin CB (2015) LI-RADS (liver imaging reporting and data system): summary, discussion, and consensus of the LI-RADS management working group and future directions. Hepatology. 61:1056–1065CrossRefPubMedGoogle Scholar
  3. 3.
    Heimbach J, Kulik LM, Finn R, et al. (2017) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology.  https://doi.org/10.1002/hep.29086 Google Scholar
  4. 4.
    Vilana R, Forner A, Bianchi L, et al. (2010) Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 51(6):2020–2029CrossRefPubMedGoogle Scholar
  5. 5.
    Li R, Yuan MX, Ma KS, et al. (2014) Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS ONE 9(5):e98612CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Wildner D, Bernatik T, Greis C, et al. (2015) CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med 36(2):132–139CrossRefPubMedGoogle Scholar
  7. 7.
    Ishak K, Baptista A, Bianchi L, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22:696–699CrossRefPubMedGoogle Scholar
  8. 8.
    Park YN (2011) Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med 135:704–715CrossRefPubMedGoogle Scholar
  9. 9.
    Coleman WB (2003) Mechanisms of human hepatocarcinogenesis. Curr Mol Med. 3:573–588CrossRefPubMedGoogle Scholar
  10. 10.
    International Working Party (1995) Terminology of nodular hepatocellular lesions. Hepatology 22:983–993CrossRefGoogle Scholar
  11. 11.
    Roskams T, Kojiro M (2010) Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis. 30:17–25CrossRefPubMedGoogle Scholar
  12. 12.
    Trevisani F, Cantarini MC, Wands JR, Bernardi M (2008) Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 29:1299–1305CrossRefPubMedGoogle Scholar
  13. 13.
    Chou CT, Chou JM, Chang TA, et al. (2013) Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging. World J Gastroenterol 19:7433–7439CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jha RC, Mitchell DG, Weinreb JC, et al. (2014) LI-RADS categorization of benign and likely benign findings in patients at risk of hepatocellular carcinoma: a pictorial atlas. AJR Am J Roentgenol 203:48–69CrossRefGoogle Scholar
  15. 15.
    Choi J-Y, Lee J-M, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma. Part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 273:30–50CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Han J, Liu Y, Han F, et al. (2015) The degree of contrast washout on contrast-enhanced ultrasound in distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma. Ultrasound Med Biol 41(12):3088–3095CrossRefPubMedGoogle Scholar
  17. 17.
    Wildner D, Pfeifer L, Goertz RS, et al. (2014) Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma. Ultraschall Med 35(6):522–527CrossRefPubMedGoogle Scholar
  18. 18.
    The Liver Imaging Reporting and Data System (LI-RADS). http://www.acr.org/quality-safety/resources/LIRADS
  19. 19.
    Kono Y, Cosgrove D, Dietrich C, et al. (2016) Contrast-enhanced ultrasound liver imaging reporting and data system for diagnosis of hepatocellular carcinoma: initial proposal. J Ultrasound Med 35(suppl):S1–S132Google Scholar
  20. 20.
    Jang HJ, Kono Y, Sirlin C, et al. (2015) Incorporation of CEUS Into LI-RADS for diagnosis of hepatocellular carcinoma (HCC): a work in progress. Radiological Society of North America Annual Meeting. 29 November–4 December 2015, Chicago, IL. GI212-ED-XGoogle Scholar
  21. 21.
    Piscaglia F, Wilson SR, Lyshchik A, et al. (2017) American college of radiology contrast enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: a pictorial essay. Ultraschall Med. 38:320–324CrossRefPubMedGoogle Scholar
  22. 22.
    Heimbach J, Kulik LM, Finn R, et al. (2017) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology.  https://doi.org/10.1002/hep.29086 Google Scholar
  23. 23.
    OPTN Policy #9: allocation of livers and liver-intestines. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf
  24. 24.
    Claudon M, Dietrich CF, Choi BI, et al. (2012) A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013(39):187–210Google Scholar
  25. 25.
    Sawhney S, Wilson SR (2017) Can ultrasound with contrast enhancement replace nonenhanced computed tomography scans in patients with contraindication to computed tomography contrast agents? Ultrasound Q 33:125–132CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Jang HJ, Kim TK, Burns PN, Wilson SR (2015) CEUS: an essential component in a multimodality approach to small nodules in patients at high-risk for hepatocellular carcinoma. Eur J Radiol 84:1623–1635CrossRefPubMedGoogle Scholar
  27. 27.
    Hanna RF, Miloushev VZ, Tang A, et al. (2016) Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY) 41:71–79CrossRefGoogle Scholar
  28. 28.
    Exuzides A, Main ML, Colby C, et al. (2010) A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent. JACC Cardiovasc Imaging 3:578–585CrossRefPubMedGoogle Scholar
  29. 29.
    Goldberg YH, Ginelli P, Siegel R, et al. (2012) Administration of perflutren contrast agents during transthoracic echocardiography is not associated with a significant increase in acute mortality risk. Cardiology 122(2):119–125CrossRefPubMedGoogle Scholar
  30. 30.
    Aggeli C, Giannopoulos G, Roussakis G, et al. (2008) Safety of myocardial flash-contrast echocardiography in combination with dobutamine stress testing for the detection of ischaemia in 5250 studies. Heart 94:1571–1577CrossRefPubMedGoogle Scholar
  31. 31.
    Parker JM, Weller MW, Feinstein LM, et al. (2013) Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts. Am J Cardiol 1(112):1039–1045CrossRefGoogle Scholar
  32. 32.
    Jo PC, Jang HJ, Burns PN, et al. (2017) Integration of Contrast-enhanced US into a multimodality approach to imaging of nodules in a cirrhotic liver: how i do it. Radiology 282:317–331CrossRefPubMedGoogle Scholar
  33. 33.
    EFSUMB (2010) Minimum training requirements for the practice of medical ultrasound in Europe. Ultraschall in Med 31:426–427CrossRefGoogle Scholar
  34. 34.
  35. 35.
    Main ML, Hibberd MG, Ryan A, et al. (2014) Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent. JACC Cardiovasc Imaging 7:40–48CrossRefPubMedGoogle Scholar
  36. 36.
    Parker JM, Weller MW, Feinstein LM, et al. (2013) Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts. Am J Cardiol 112:1039–1045CrossRefPubMedGoogle Scholar
  37. 37.
    Main ML, Ryan AC, Davis TE, et al. (2008) Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). Am J Cardiol. 102:1742–1746CrossRefPubMedGoogle Scholar
  38. 38.
    Wei K, Mulvagh SL, Carson L, et al. (2008) The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr 21:1202–1206CrossRefPubMedGoogle Scholar
  39. 39.
    Herzog CA (2008) Incidence of adverse events associated with use of perflutren contrast agents for echocardiography. JAMA 299:2023–2025CrossRefPubMedGoogle Scholar
  40. 40.
  41. 41.
    Muskula PR, Main ML (2017) Safety With echocardiographic contrast agents. Circ Cardiovasc Imaging.  https://doi.org/10.1161/CIRCIMAGING.116.005459 PubMedGoogle Scholar
  42. 42.
  43. 43.
  44. 44.
    Yu H, Jang HJ, Kim TK, et al. (2010) Pseudo-enhancement within local ablation zone of hepatic tumors due to nonlinear artifact on contrast-enhanced ultrasound. Am J Roentgenol 194:653–659CrossRefGoogle Scholar
  45. 45.
    Dietrich CF, Ignee A, Greis C, et al. (2014) Artifacts and pitfalls in contrast-enhanced ultrasound of the liver. Ultraschall Med 35(2):108–125CrossRefPubMedGoogle Scholar
  46. 46.
    Li SY, Huang P, Cosgrove D, et al. (2016) Pseudoenhancement of gallbladder sludge: a confusing artifact caused by nonlinear propagation of ultrasound through microbubbles. Ultraschall Med 37(3):307–309CrossRefPubMedGoogle Scholar
  47. 47.
    Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR (2017) LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY).  https://doi.org/10.1007/s00261-017-1196-2 Google Scholar
  48. 48.
    Hanna RF, Aguirre DA, Kased N, et al. (2008) Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics 28:747–769CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  • Andrej Lyshchik
    • 1
  • Yuko Kono
    • 2
  • Christoph F. Dietrich
    • 3
  • Hyun-Jung Jang
    • 4
  • Tae Kyoung Kim
    • 4
  • Fabio Piscaglia
    • 5
  • Alexander Vezeridis
    • 6
  • Juergen K. Willmann
    • 7
  • Stephanie R. Wilson
    • 8
  1. 1.Department of RadiologyThomas Jefferson University HospitalPhiladelphiaUSA
  2. 2.Departments of Medicine and RadiologyUniversity of CaliforniaSan DiegoUSA
  3. 3.Department of Internal Medicine 2Caritas-Krankenhaus Bad MergentheimBad MergentheimGermany
  4. 4.Department of Medical ImagingUniversity of TorontoTorontoCanada
  5. 5.Unit of Internal Medicine, Department of Medical and Surgical SciencesS. Orsola-Malpighi Hospital, University of BolognaBolognaItaly
  6. 6.Department of RadiologyUniversity of CaliforniaSan DiegoUSA
  7. 7.Department of RadiologyStanford UniversityStanfordUSA
  8. 8.Division of GastroenterologyUniversity of CalgaryCalgaryCanada

Personalised recommendations